News | January 09, 2025
Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery
Increases speed to market for drug developers working on nucleic acid therapeutics
Increases speed to market for drug developers working on nucleic acid therapeutics
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
Construction will begin this year with the new capacity anticipated by 2025
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Subscribe To Our Newsletter & Stay Updated
